Camlipixant is an
investigational new drug
The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical industry, pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug inte ...
that is being evaluated for the treatment of chronic
cough
A cough is a sudden expulsion of air through the large breathing passages which can help clear them of fluids, irritants, foreign particles and Microorganism, microbes. As a protective reflex, coughing can be repetitive with the cough reflex fol ...
.
It is a
P2X3 receptor antagonist.
See also
*
gefapixant
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor.
It was authorized for medical use in the European Union in September 2023.
Medical uses ...
References
Benzamides
Carbamates
Morpholines
Imidazopyridines
{{respiratory-system-drug-stub